(Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceutical company developing innovative drug candidates for the prevention and treatment of cancer, yesterday presented an update of the ongoing clinical study LDOS002 for their drug candidate L‐DOS47 during the 16th World Conference on Lung Cancer held in Denver Colorado.
- 0 Comments
- FY2016